awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q52686509-4459F707-AAB7-4D6F-91F3-F2A3DA8ADECC
Q52686509-4459F707-AAB7-4D6F-91F3-F2A3DA8ADECC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52686509-4459F707-AAB7-4D6F-91F3-F2A3DA8ADECC
Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
P2860
Q52686509-4459F707-AAB7-4D6F-91F3-F2A3DA8ADECC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52686509-4459F707-AAB7-4D6F-91F3-F2A3DA8ADECC
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
86c82e91a18b0ba65eb298f1ced903a9323c0519
P2860
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.